The cancer drug dasatinib increases pgc-1α in adipose tissue but has adverse effects on glucose tolerance in obese mice

Lykke Sylow, Jonathan Z. Long, Isha A. Lokurkar, Xing Zeng, Erik A. Richter, Bruce M. Spiegelman

Research output: Contribution to journalArticlepeer-review

Abstract

Dasatinib (Sprycel) is a tyrosine kinase inhibitor approved for treatment of chronic myeloid leukemia. In this study, we identify dasatinib as a potent inducer of Peroxisome proliferator-Activated receptor gamma coactivator (PGC)-1α mRNA. Dasatinib increased PGC-1α mRNA expression up to 6-fold in 3T3-F442A adipocytes, primary adipocytes, and epididymal white adipose tissue from lean and diet-induced obese mice. Importantly, gene expression translated into increased PGC-1α protein content analyzed in melanoma cells and isolated mitochondria from adipocytes. However, dasatinib treatment had adverse effect on glucose tolerance in diet-induced obese and Ob/Ob mice. This correlated with increased hepatic PGC-1α expression and the gluconeogenesis genes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. In conclusion, we show that dasatinib is a potent inducer of PGC-1α mRNA and protein in adipose tissue. However, despite beneficial effects of increased PGC-1α content in adipose tissue, dasatinib significantly impaired glucose tolerance in obese but not lean mice. As far as we are aware, this is the first study to show that dasatinib regulates PGC-1α andcauses glucose intolerance in obese mice. This should be considered in the treatment of chronic myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)4184-4191
Number of pages8
JournalEndocrinology
Volume157
Issue number11
DOIs
StatePublished - Nov 2016
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology

Fingerprint

Dive into the research topics of 'The cancer drug dasatinib increases pgc-1α in adipose tissue but has adverse effects on glucose tolerance in obese mice'. Together they form a unique fingerprint.

Cite this